underpar71,
One simple question, why hasn’t L, that works with no question about safety since 2012, not been given the support from anywhere except the UK Specials Program to get to otherwise terminal patients on a more wide scale basis? That’s not a NWBO problem. That’s a challenge to status quo problem and we all know this by now.
This should have been more widely available for terminal patients years ago even if only private pay and advocate group sponsored. That would have interfered with the plans of others wanting those patients for their own studies. “The process” is what is shady and we all know this. “The process” has kept many good treatments from reaching patients in a more timely manner and history is littered with plenty of examples of this as well as examples of treatments that should not have made it through but did because of influence peddling. It’s not DCVax or NWBO that is the problem here. It’s those who know the truth and stand in the way or can’t find a way to get out of the way fast enough because the status quo has them entrenched. Otherwise this treatment would be getting to patients more often already because artisan manufacturing was safe enough for patients during the trial so insisting on anything beyond that is just overkill even if needed to lower cost to a strapped healthcare system and get NWBO to a business model that works for faster expansion. Bottom line is there is ONLY ONE REASON this wait can be justified and that is the desire to get this treatment to as many CANCER patients as soon as possible and that would require more production capacity data review, regulatory scrutiny and planning to justify this move. I am not advocating that this will instantly be tissue agnostic but planning for this, if being considered longer term because of the Specials data and other, must be done now in my opinion which is backed by the IFR change to cancer indication from GBM and moves by Advent to plan for increased leukapheresis demand and transition to Flaskworks for all future expansion done just recently. Best wishes.
Market Data 
Markets 
AI
